NCT02012231 2020-10-19Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.Fore BiotherapeuticsPhase 1 Terminated5 enrolled